Cardiff Oncology (NASDAQ: CRDF – Get Rating) and Sorrento Therapeutics (NASDAQ: SRNE – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.
Earnings and Valuation:
This table compares Cardiff Oncology and Sorrento Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue:||Price / Sales Ratio:||Net Income:||Earnings Per Share:||Price / Earnings Ratio:|
|Cardiff Oncology:||$ 360,000.00:||275.47:||– $ 28.29 million:||($ 0.82)||-2.79:|
|Sorrento Therapeutics:||$ 52.90 million:||16.76:||– $ 428.33 million:||($ 1.23)||-1.85:|
Cardiff Oncology has higher earnings, but lower revenue than Sorrento Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the most affordable of the two stocks.
This is a breakdown of recent recommendations and price targets for Cardiff Oncology and Sorrento Therapeutics, as provided by MarketBeat.
|Sell Ratings:||Hold Ratings:||Buy Ratings:||Strong Buy Ratings:||Rating Score:|
Cardiff Oncology currently has a consensus target price of $ 13.75, indicating a potential upside of 500.44%. Sorrento Therapeutics has a consensus target price of $ 20.00, indicating a potential upside of 777.19%. Given Sorrento Therapeutics’ higher probable upside, analysts plainly believe Sorrento Therapeutics is more favorable than Cardiff Oncology.
Volatility & Risk:
Cardiff Oncology has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.
This table compares Cardiff Oncology and Sorrento Therapeutics’ net margins, return on equity and return on assets.
|Net Margins:||Return on Equity:||Return on Assets:|
Insider and Institutional Ownership:
56.4% of Cardiff Oncology shares are held by institutional investors. Comparatively, 27.0% of Sorrento Therapeutics shares are held by institutional investors. 3.5% of Cardiff Oncology shares are held by company insiders. Comparatively, 3.3% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Cardiff Oncology beats Sorrento Therapeutics on 8 of the 13 factors compared between the two stocks.
About Cardiff Oncology: (Get Rating)
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b / 2 for FOLFIRI and bevacizumab. The company TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
About Sorrento Therapeutics: (Get Rating)
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I / II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
Receive News & Ratings for Cardiff Oncology Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cardiff Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.